Gary, sorry for the slow response, just catching up. Thx for the reply.
The only points I would add is the patent owning company can restrict use of their proprietary property, in this case probably mostly the mfg process, from others using it. If say a BP wanted to use DCVax in a combination with their product there may be a way around the patent protections but I do not think they would use it since they need to have all the supporting science and studies and current market knowledge post approval to effectively use it in a submission. They would not have any of that until the patent expired and would have to generate it on their own. There would typically be a licensing agreement which would afford them all the necessary data,...ongoing medical and scientific support.
The other point is Genentech was a stand alone company with all required functions built to support marketed products. NWBO can build what they need but I have a hard time seeing it as they need more than they have, particularly if they now want to accelerate platform development, which they would be wise to do since patents have life spans and competition will now accelerate. I think at the least they need a broad strategic partnership focused on commercialization and platform development with licensing rights priority to the partner as development progresses. To date they have shown signs to me of considering themselves a product development company who will sell themselves but a licensing royalty stream may serve the purpose to cover a limited time period.
GLTA
News 
Market Data 
Discover 
AI
